UBS Maintains Buy on Applied Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Esther Rajavelu maintains a Buy rating on Applied Therapeutics (NASDAQ:APLT) and raises the price target from $4 to $12.
March 06, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Esther Rajavelu has maintained a Buy rating on Applied Therapeutics and increased the price target from $4 to $12.
The significant increase in the price target by a reputable analyst suggests a strong bullish outlook on Applied Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100